WHO naming stem · suffix · 6 listed names
-tegravir
This page was written with AI.
HIV integrase inhibitors
Where it sits in a name
WHO writes the stem as -tegravir. So the letters tegravir sit at the end of the name (…tegravir).
All 6 names WHO lists under -tegravir
These are the INN in group (a) of Part IV of the stem book: names in which WHO says the stem is used as defined. The stem is marked where WHO places it. A-Z as WHO lists them.
Beside each name: the brand names it appears under in the US list (FDA Drugs@FDA) and the EU central list (EMA), or that neither list carries it. 5 of 6 names appear in these lists: 5 in the US list (FDA Drugs@FDA) and 5 in the EU central list (EMA); 3 have national brands in at least one EU/EEA country. Each brand opens in this site's brand lookup. A name is found when the agency's ingredient name is the same name once salt words such as hydrochloride or sodium are set aside (the list of those words); where WHO's own name carries such a word (estradiol valerate), the agency must write the same words. A spelling that differs only by the INN letter rules (ph for f, y for i) is found too and shown. Under each name that one or more EU/EEA countries authorise under a national brand of their own (through that country's agency, so not in the EU central list), a line now gives the number of those countries and their codes, from EMA's Article 57 data, and opens the country lookup at that name. A name with none of these lines may still be sold elsewhere, or in Europe only under its own generic name.
- bictegravirUS brands, in combination: BIKTARVY with emtricitabine + tenofovir alafenamide; BIXLENVO with lenacapavir; BIXLENVO SUNLENCA STARTER PACK (COPACKAGED) with lenacapavir
- cabotegravir
- dolutegravirin combination: DOVATO with lamivudine; JULUCA with rilpivirine; TRIUMEQ with abacavir + lamivudine; TRIUMEQ PD with abacavir + lamivudineEU (central) brands: Tivicay
- elvitegravir
- pirmitegravirNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- raltegravirEU (central) brands: Isentress
US list: Drugs@FDA, from the FDA Drugs@FDA data (openFDA bulk file), checked . It keeps discontinued brands, marked here as FDA marks them.
EU (central) list: EMA medicines list, European Medicines Agency (EMA), checked . Medicines authorised for the whole EU through EMA only: a brand authorised by one country's own agency is not in it. Source: European Medicines Agency (EMA), medicines list, checked 2026-09-24.
EU/EEA national lists: European Medicines Agency (EMA), Article 57 product data, downloaded (EMA's Article 57 page). Brand names authorised by each country's own agency, as the country lookup reads them; a product named after its substance and maker ("Paracetamol Teva") is not counted as a brand, and EU central authorisations are not counted as a country. GB in a list is Northern Ireland, which EMA's data carries alongside the EU/EEA countries.
Decode another name
Decoded
bictegravir
Listed INNCarries 2 WHO stems, most specific first: -tegravir …
- -tegravirend of the nameWHO lists it hereWHO definition: HIV integrase inhibitors
- virend of the nameWHO definition: antivirals (undefined group)
“bictegravir” is an INN that WHO lists under -tegravir in the 2024 stem book.
The same decoder as the front page: it reads the letters of a name against all 482 WHO stems, in your browser.
Source and licence
The definition of -tegravir (Part II B) and the 6 names (Part IV, group (a)) are from Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024 (World Health Organization, Stem book 2024 (ISBN 978-92-4-009938-8); covers proposed INN Lists 1-129). Checked .
Adapted from: Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO. This adaptation was not created by WHO; WHO is not responsible for its content or accuracy and does not endorse this site. The data file stems.json is shared under the same licence.